TRAVERE THERAPEUTICS INC. 2024-2025 Proxy Voting Records

Description as filed by funds: To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for a term of one year: Eric Dube

TRAVERE THERAPEUTICS INC.’s own tally for this item (“Elect Director: Eric Dube, Ph.D.”): 74,221,146 for, 433,867 withheld, per its Form 8-K filed May 16, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors The Company's stockholders elected the ten persons listed below to serve until the Company's 2026 Annual Meeting of Stockholders.”
Support: 99.4% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 70 asset managers below reported 27,191,016 for, 4,123 withheld.

Showing the 25 largest of 70 asset managers. See all 70 in the interactive database.

Description as filed by funds: To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for a term of one year: Gary Lyons

TRAVERE THERAPEUTICS INC.’s own tally for this item (“Elect Director: Gary Lyons”): 73,773,536 for, 881,477 withheld, per its Form 8-K filed May 16, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors The Company's stockholders elected the ten persons listed below to serve until the Company's 2026 Annual Meeting of Stockholders.”
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 70 asset managers below reported 27,190,651 for, 4,488 withheld.

Showing the 25 largest of 70 asset managers. See all 70 in the interactive database.

Description as filed by funds: To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for a term of one year: Jeffrey Meckler

TRAVERE THERAPEUTICS INC.’s own tally for this item (“Elect Director: Jeffrey Meckler”): 71,792,648 for, 2,862,365 withheld, per its Form 8-K filed May 16, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors The Company's stockholders elected the ten persons listed below to serve until the Company's 2026 Annual Meeting of Stockholders.”
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 70 asset managers below reported 27,032,259 for, 51,255 withheld, 111,625 abstained.

Showing the 25 largest of 70 asset managers. See all 70 in the interactive database.

Description as filed by funds: To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for a term of one year: John Orwin

TRAVERE THERAPEUTICS INC.’s own tally for this item (“Elect Director: John A. Orwin”): 73,064,344 for, 1,590,669 withheld, per its Form 8-K filed May 16, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors The Company's stockholders elected the ten persons listed below to serve until the Company's 2026 Annual Meeting of Stockholders.”
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 70 asset managers below reported 27,136,883 for, 58,256 withheld.

Showing the 25 largest of 70 asset managers. See all 70 in the interactive database.

Description as filed by funds: To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for a term of one year: Ron Squarer

TRAVERE THERAPEUTICS INC.’s own tally for this item (“Elect Director: Ron Squarer”): 74,003,330 for, 651,683 withheld, per its Form 8-K filed May 16, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors The Company's stockholders elected the ten persons listed below to serve until the Company's 2026 Annual Meeting of Stockholders.”
Support: 99.1% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 70 asset managers below reported 27,191,016 for, 4,123 withheld.

Showing the 25 largest of 70 asset managers. See all 70 in the interactive database.

Description as filed by funds: To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for a term of one year: Roy Baynes

TRAVERE THERAPEUTICS INC.’s own tally for this item (“Elect Director: Roy D. Baynes, M.D., Ph.D.”): 73,899,556 for, 755,457 withheld, per its Form 8-K filed May 16, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors The Company's stockholders elected the ten persons listed below to serve until the Company's 2026 Annual Meeting of Stockholders.”
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 70 asset managers below reported 27,182,505 for, 12,634 withheld.

Showing the 25 largest of 70 asset managers. See all 70 in the interactive database.

Description as filed by funds: To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for a term of one year: Ruth Williams-Brinkley

TRAVERE THERAPEUTICS INC.’s own tally for this item (“Elect Director: Ruth Williams-Brinkley”): 74,000,702 for, 654,311 withheld, per its Form 8-K filed May 16, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors The Company's stockholders elected the ten persons listed below to serve until the Company's 2026 Annual Meeting of Stockholders.”
Support: 99.1% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 70 asset managers below reported 27,191,016 for, 4,123 withheld.

Showing the 25 largest of 70 asset managers. See all 70 in the interactive database.

Description as filed by funds: To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for a term of one year: Sandra Poole

TRAVERE THERAPEUTICS INC.’s own tally for this item (“Elect Director: Sandra Poole”): 73,951,215 for, 703,798 withheld, per its Form 8-K filed May 16, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors The Company's stockholders elected the ten persons listed below to serve until the Company's 2026 Annual Meeting of Stockholders.”
Support: 99.0% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 70 asset managers below reported 27,182,506 for, 12,633 withheld.

Showing the 25 largest of 70 asset managers. See all 70 in the interactive database.

Description as filed by funds: To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for a term of one year: Suzanne Bruhn

TRAVERE THERAPEUTICS INC.’s own tally for this item (“Elect Director: Suzanne Bruhn, Ph.D.”): 73,883,211 for, 771,802 withheld, per its Form 8-K filed May 16, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors The Company's stockholders elected the ten persons listed below to serve until the Company's 2026 Annual Meeting of Stockholders.”
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 70 asset managers below reported 27,191,016 for, 4,123 withheld.

Showing the 25 largest of 70 asset managers. See all 70 in the interactive database.

Description as filed by funds: To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for a term of one year: Timothy Coughlin

TRAVERE THERAPEUTICS INC.’s own tally for this item (“Elect Director: Timothy Coughlin”): 73,659,261 for, 995,752 withheld, per its Form 8-K filed May 16, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors The Company's stockholders elected the ten persons listed below to serve until the Company's 2026 Annual Meeting of Stockholders.”
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 70 asset managers below reported 27,079,026 for, 4,488 withheld, 111,625 abstained.

Showing the 25 largest of 70 asset managers. See all 70 in the interactive database.

Description as filed by funds: To approve the Company's 2018 Equity Incentive Plan, as amended, to increase the number of shares of common stock authorized for issuance thereunder by 4,000,000 shares.

TRAVERE THERAPEUTICS INC.’s own tally for this item (“2. Approval of the Company's 2018 Equity Incentive Plan, as amended”): 71,802,001 for, 2,812,989 against — passed, per its Form 8-K filed May 16, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 2: Approval of the Company's 2018 Equity Incentive Plan, as amended The Company's stockholders approved the 2018 Plan, as amended, to increase the number of shares of common stock authorized for issuance thereunder by 4,000,000.”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 70 managers: 26,571,283 for, 619,733 against, 4,123 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 4 managers: 1,089,690 for.

Description as filed by funds: To approve, on an advisory basis, the compensation of the Company's named executive officers.

TRAVERE THERAPEUTICS INC.’s own tally for this item (“3. Approval, on an advisory basis, of the compensation of the Company's named executive officers”): 71,929,269 for, 2,677,694 against — passed, per its Form 8-K filed May 16, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 3: Approval, on an advisory basis, of the compensation of the Company's named executive officers The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers.”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 70 managers: 27,031,182 for, 159,834 against, 4,123 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 179 managers: 58,120,964 for, 1,530,343 against, 1,016 abstained, 17 not voted. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: To ratify the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025.

TRAVERE THERAPEUTICS INC.’s own tally for this item (“4. Ratification of the Selection of Independent Registered Public Accounting Firm”): 79,001,421 for, 46,742 against — passed, per its Form 8-K filed May 16, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 4: Ratification of the Selection of Independent Registered Public Accounting Firm The Company's stockholders ratified the selection by the Audit Committee of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 73 asset managers below reported 27,192,709 for, 4,123 abstained.

Showing the 25 largest of 73 asset managers. See all 73 in the interactive database.